尊龙凯时·「中国区」官方网站

2024-10-16 The Phase III Clinical Trial Application in China of the Global Innovative RDC Drug of the Group ITM-11 Was Accepted by NMPA

2024-10-15 Grand Pharma Presents at the 28th Congress of Chinese Ophthalmological Society

2024-09-04 Grand Pharma Presents at the 2024 Annual National Rhinology Conference

2024-08-29 Grand Pharma Supports China Dean’s Conference to Deepen the Practice of “Three Doctors’ Cooperation

2024-08-08 Chengdu Purevalley Medical Technology New Construction Project of Radionuclide Temporary Storage Workplace Environmental Impact Assessment Report Sheet Full Public Notice

2024-07-22 Grand Pharma Completed the Acquisition of Tianjin Tanabe and Baiji Pharmaceutical

2024-06-28 Sirtex Medical Partners with MediTrust Health to Explore Innovative Payment Models for Liver Tumor Patients in China

2024-06-26 Grand Pharma at the Respiratory Event: Sharing Cutting-Edge Theories and Clinical Applications in Respiratory Medicine

2024-06-26 Grand Pharma Appears at the 88th PHARMCHINA

2024-06-11 The Phase I Clinical Study Conducted in China of the Grand Pharma’s Global Innovative Ophthalmic Drug GPN00884 Has Completed the First Patient Enrollment

2024-05-31 Grand Pharma 2024 Investor Open Day

2024-04-24 Employer Presentations at Wuhan University and Huazhong University of Science and Technology